Bharat Biotech International Limited: A Phase II/III, Open Label, Multicenter Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Whole-Virion Inactivated SARS-CoV-2 Vaccine (COVAXIN®) in Healthy Volunteers Ages ≤18 to ≥ 2 Years. NCT04918797. clinicaltrials.gov, 17. August 2022 (clinicaltrials.gov [abgerufen am 17. November 2022]).
Peter J. Hotez, Maria Elena Bottazzi: Whole Inactivated Virus and Protein-Based COVID-19 Vaccines. In: Annual Review of Medicine. 73. Jahrgang, Nr.1, 27. Januar 2022, S.55–64, doi:10.1146/annurev-med-042420-113212, PMID 34637324 (englisch).
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. In: The Lancet. 398. Jahrgang, Nr.10317, 11. November 2021, S.2173–2184, doi:10.1016/S0140-6736(21)02000-6, PMID 34774196, PMC 8584828 (freier Volltext) – (englisch).
Bi Wang, Simon Van Herck, Yong Chen, Xiangyang Bai, Zifu Zhong, Kim Deswarte, Bart N. Lambrecht, Niek N. Sanders, Stefan Lienenklaus, Hans W. Scheeren, Sunil A. David, Fabian Kiessling, Twan Lammers, Bruno G. De Geest, Yang Shi: Potent and Prolonged Innate Immune Activation by Enzyme-Responsive Imidazoquinoline TLR7/8 Agonist Prodrug Vesicles. In: Journal of the American Chemical Society. Band142, Nr.28, 15. Juli 2020, S.12133–12139, doi:10.1021/jacs.0c01928, PMC 7116109 (freier Volltext).
Priyanka Pulla: Exports of an Indian COVID-19 vaccine halted after WHO finds problems at manufacturing plant. In: Science. 7. April 2022, doi:10.1126/science.abq4311 (englisch).
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. In: The Lancet. Infectious Diseases. 21. Jahrgang, Nr.5, Mai 2021, S.637–646, doi:10.1016/S1473-3099(20)30942-7, PMID 33485468, PMC 7825810 (freier Volltext) – (englisch).
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. In: The Lancet. Infectious Diseases. 21. Jahrgang, Nr.7, März 2021, S.950–961, doi:10.1016/S1473-3099(21)00070-0, PMID 33705727, PMC 8221739 (freier Volltext) – (englisch).
India Correspondent Bmj: India: Doctors call for investigation into allegations of ethical abuse in covid-19 vaccine trial. In: BMJ. Band372, 14. Januar 2021, S.n131, doi:10.1136/bmj.n131, PMID 33446480.
Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees. In: Clinical Infectious Diseases. 74. Jahrgang, Nr.2, Mai 2021, S.366–368, doi:10.1093/cid/ciab411, PMID 33961693 (englisch).
Pragya D. Yadav, Gajanan N. Sapkal, Raches Ella, Rima R. Sahay, Dimpal A Nyayanit, Deepak Y. Patil, Gururaj Deshpande, Anita M. Shete, Nivedita Gupta, V. Krishna Mohan, Priya Abraham, Samiran Panda, Balram Bhargava: Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152. Microbiology, 7. Juni 2021, doi:10.1101/2021.06.05.447177.
Kamala Thiagarajan: What do we know about India’s Covaxin vaccine? In: BMJ. Band373, 20. April 2021, S.n997, doi:10.1136/bmj.n997, PMID 33879478.
Peter J. Hotez, Maria Elena Bottazzi: Whole Inactivated Virus and Protein-Based COVID-19 Vaccines. In: Annual Review of Medicine. 73. Jahrgang, Nr.1, 27. Januar 2022, S.55–64, doi:10.1146/annurev-med-042420-113212, PMID 34637324 (englisch).
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. In: The Lancet. 398. Jahrgang, Nr.10317, 11. November 2021, S.2173–2184, doi:10.1016/S0140-6736(21)02000-6, PMID 34774196, PMC 8584828 (freier Volltext) – (englisch).
Bi Wang, Simon Van Herck, Yong Chen, Xiangyang Bai, Zifu Zhong, Kim Deswarte, Bart N. Lambrecht, Niek N. Sanders, Stefan Lienenklaus, Hans W. Scheeren, Sunil A. David, Fabian Kiessling, Twan Lammers, Bruno G. De Geest, Yang Shi: Potent and Prolonged Innate Immune Activation by Enzyme-Responsive Imidazoquinoline TLR7/8 Agonist Prodrug Vesicles. In: Journal of the American Chemical Society. Band142, Nr.28, 15. Juli 2020, S.12133–12139, doi:10.1021/jacs.0c01928, PMC 7116109 (freier Volltext).
F. Hoeksema, J. Karpilow, A. Luitjens, F. Lagerwerf, M. Havenga, M. Groothuizen, G. Gillissen, A.A.C. Lemckert, B. Jiang, R.A. Tripp, C. Yallop: Enhancing viral vaccine production using engineered knockout vero cell lines – A second look. In: Vaccine. Band36, Nr.16, 12. April 2018, S.2093–2103, PMID 29555218, PMC 5890396 (freier Volltext).
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. In: The Lancet. Infectious Diseases. 21. Jahrgang, Nr.5, Mai 2021, S.637–646, doi:10.1016/S1473-3099(20)30942-7, PMID 33485468, PMC 7825810 (freier Volltext) – (englisch).
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. In: The Lancet. Infectious Diseases. 21. Jahrgang, Nr.7, März 2021, S.950–961, doi:10.1016/S1473-3099(21)00070-0, PMID 33705727, PMC 8221739 (freier Volltext) – (englisch).
India Correspondent Bmj: India: Doctors call for investigation into allegations of ethical abuse in covid-19 vaccine trial. In: BMJ. Band372, 14. Januar 2021, S.n131, doi:10.1136/bmj.n131, PMID 33446480.
Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees. In: Clinical Infectious Diseases. 74. Jahrgang, Nr.2, Mai 2021, S.366–368, doi:10.1093/cid/ciab411, PMID 33961693 (englisch).
Kamala Thiagarajan: What do we know about India’s Covaxin vaccine? In: BMJ. Band373, 20. April 2021, S.n997, doi:10.1136/bmj.n997, PMID 33879478.